Early Conversion of Intensive Insulin Therapy to IDegLira Demonstrates Higher Efficacy and Safety in Reducing Fasting Blood Glucose and HbA1c in T2DM Patients
Caiyun Guo,Yang Lu
DOI: https://doi.org/10.2147/dmso.s472174
2024-09-01
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Caiyun Guo, Yang Lu Department of Endocrinology, YuYao People's Hospital, Ningbo, Zhejiang Province, People's Republic of China Correspondence: Caiyun Guo, Department of Endocrinology, YuYao People's Hospital, 800 Chengdong Road, Ningbo, Zhejiang Province, 315400, People's Republic of China, Email Background: A short-term insulin intensive therapy is an important method used in clinical practice to control blood glucose, and a scientific post-treatment plan is key to long-term blood glucose stability control. This study aimed to investigate efficacy and safety of early conversion of intensive insulin therapy to IDegLira in T2DM patients. Methods: This study was a prospective study, involving 80 T2DM patients finally. Patients were firstly treated with insulin for intensified therapy (Pre-IDegLira group), then switched to insulin degludec and liraglutide (IDegLira) for 3 months (IDegLira-3 months group). Data including HbA1c, fasting blood glucose, fasting C-peptide, weight, insulin dosage, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were analyzed. Correlations between fasting blood glucose and other parameters were evaluated with Pearson correlation analysis. Results: IDegLira early conversion significantly reduced fasting blood glucose ( p < 0.001), weight ( p =0.015), and insulin dosage ( p =0.001) of T2DM patients compared to those of Pre-IDegLira group. HbA1c level was remarkably lower in T2DM patients underwent IDegLira early conversion compared to that in Pre-IDegLira group ( p < 0.001), with HbA1c < 7% proportion of 73.75% (59/80). IDegLira early conversion significantly downregulated levels of TC ( p < 0.001), TG ( p < 0.001), LDL-C ( p < 0.001), and upregulated HDL-C level ( p =0.017) of T2DM patients, compared to those in Pre-IDegLira group. IDegLira early conversion markedly reduced ALT ( p < 0.001) and AST ( p =0.002) levels of T2DM patients compared to those in Pre-IDegLira group. IDegLira early conversion demonstrated a positive correlation between fasting blood glucose and HbA1c ( r =0.531, p < 0.001) or TG level ( r =0.336, p =0.002) in T2DM patients. Conclusion: Early conversion of intensive insulin therapy to IDegLira effectively reduced fasting blood glucose and HbA1c in T2DM patients with higher safety. Keywords: insulin intensive therapy, IDegLira, T2DM, early conversion, safety In recent 30 years, the prevalence of diabetes mellitus in China has increased significantly. 1,2 The epidemiological survey of diabetes mellitus conducted by the Endocrinology Branch of the Chinese Medical Association in 31 provinces from 2015 to 2017 showed that the prevalence rate of diabetes mellitus among people aged 18 years and above in China was 11.2%, the treatment rate was 32.2%, and the control rate was 49.2%. 3 The metabolic control of type 2 diabetes (T2DM) is still a huge challenge. The ideal treatment plan for diabetes mellitus should reduce the risk of weight gain and hypoglycemia as much as possible on the basis of effectively reducing the blood sugar level, with less adverse reactions and good compliance. Basic insulin supplements exogenous basic insulin, inhibits liver glycolysis and gluconeogenesis, reduces liver glucose output, increases skeletal muscle glucose uptake, and effectively controls fasting blood sugar. 4 The use of glucagon like peptide-1 receptor agonist (GLP-1RA) alone, 5 combined with basal insulin, can reduce the risk of hypoglycemia and weight loss. 6–8 However, both are injectable preparations, and the increased complexity of the treatment plan may reduce patient compliance. In 2020, ADA medical diagnosis and treatment standards for diabetes recommend a compound preparation of basic insulin combined with GLP-1RA at a fixed proportion. 9 Insulin degludec and liraglutide (IDegLira) is the world's first marketed combination of basal insulin and GLP-1RA, which can exert complementary regulatory metabolic effects on multiple target organs of T2DM. It is a new choice after insulin intensive therapy. A previous study 10 has shown that after 26 weeks of treatment with IDegLira, patients have significantly improved (decreased) HbA1c and a lower risk of hypoglycemia. Therefore, IDegLira can become a new option for initiating and optimizing insulin therapy in Chinese T2DM patients. This study investigated the efficacy and safety of early conversion of intensive insulin therapy to IDegLira in T2DM patients. After controlling blood glucose levels in pat -Abstract Truncated-
endocrinology & metabolism